Last reviewed · How we verify
NCT05432128
To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer
trial in Lung Cancer in 600 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Singlera Genomics Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 1 January 2020 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Singlera Genomics Inc.
Who can join
Adults 18 to 75, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This topic to take large multicenter study real world, the advanced liquid biopsy will ctDNA methylation detection technique is applied to pulmonary nodules differential diagnosis and early lung cancer screening, validation of early lung cancer screening and diagnosis of molecular classification system model, the feasibility of the development of early lung cancer screening and diagnosis of molecular classification system, improve its early screening early detection accuracy and efficiency, Improve the survival status of lung cancer high-risk population. At the same time, this project combined AI analysis technology of LDCT image results with ctDNA methylation detection, so as to overcome false negatives caused by the deficiency of ctDNA methylation detection technology in sensitivity, specificity, stability and flux, and correct false positive results that may be caused by AI analysis technology of LDCT image results. The combination of the two can avoid missed diagnosis and over - examination and over - treatment.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cell-free DNA approaches for cancer early detection and interception.
Medina JE, Dracopoli NC, Bach PB, Lau A, et al · · 2023 · cited 64× · PMID 37696619 · DOI 10.1136/jitc-2022-006013 -
Screening for pancreatic cancer has the potential to save lives, but is it practical?
Mazer BL, Lee JW, Roberts NJ, Chu LC, et al · · 2023 · cited 23× · PMID 37212770 · DOI 10.1080/17474124.2023.2217354 -
Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.
Garbo E, Del Rio B, Ferrari G, Cani M, et al · · 2023 · cited 11× · PMID 37835468 · DOI 10.3390/cancers15194774 -
Enhancing the differential diagnosis of small pulmonary nodules: a comprehensive model integrating plasma methylation, protein biomarkers, and LDCT imaging features.
Yang M, Yu H, Feng H, Duan J, et al · · 2024 · cited 6× · PMID 39482707 · DOI 10.1186/s12967-024-05723-5 -
Revolution of Circulating Tumor DNA: From Bench Innovations to Bedside Implementations.
Yan X, Su J, Wang Z. · · 2025 · cited 1× · PMID 40699826 · DOI 10.3390/cimb47060428 -
Genomic-Based Early Detection Screening: A Literature Review of Prospective Trials and Emerging Strategies for Gastrointestinal Cancers.
Tizpa E, Sharzehi K, Nabavizadeh N. · · 2024 · PMID 39246640 · DOI 10.7759/cureus.68881
Verify or expand the search:
- PubMed search for NCT05432128
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Singlera Genomics Inc. trials
Trials by the same sponsor.
- NCT06842563 — Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinica · active not recruiting
- NCT06440018 — INSPIRE: a Multi-Cancer Early Detection Study · recruiting
- NCT06895551 — Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection · completed
- NCT05485077 — A Prospective Cohort Study on Colorectal Cancer Screening in Community Population · recruiting
- NCT05444491 — Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05432128 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Singlera Genomics Inc.
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05432128.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing